Cancer Research and Treatment

Original Articles

Effect of Oral Supplementation with Branched-chain Amino Acid (BCAA) during Radiotherapy in Patients with Hepatocellular Carcinoma: A Double-Blind Randomized Study: Ik Jae Lee, Jinsil Seong, Jung Im Bae, Sei Hwan You, Yumie Rhee, Jong Ho Lee; Cancer Res Treat. 2011;43(1):24-31. Published online March 31, 2011; DOI: https://doi.org/10.4143/crt.2011.43.1.24

PURPOSE
The present study evaluated whether oral supplementation with a branched-chain amino acid (BCAA) improves the biochemical and amino acid profiles of liver tumor patients undergoing radiotherapy.
MATERIALS AND METHODS
Patients were randomly assigned to one of 2 groups: a group given oral supplementation with BCAA granules (LIVACT granules; Samil Pharm Co., Korea, each granule containing L-isoleucine 952 mg, L-leucine 1,904 mg, and L-valine 1,144 mg) during radiotherapy, or a placebo group. Physical and biochemical examinations and measurements, including subjective symptoms, Child-Pugh class, body mass index, plasma albumin concentration, and plasma amino acid profiles were monitored.
RESULTS
Fifty were enrolled between November 2005 and November 2006. We also analyzed data from 37 hepatocellular carcinoma (HCC) patients in order to evaluate a more homogenous group. The two groups of patients were comparable in terms of age, gender, Child-Pugh score, and underlying hepatitis virus type. Serum albumin, total protein, liver enzymes, and cholesterol showed a tendency to increase in the BCAA group. In this group, the percentage of cases that reverted to normal serum albumin levels between 3 and 10 weeks after administration of BCAA was significantly higher (41.18%) than in the placebo group (p=0.043).
CONCLUSION
Oral supplementation with a BCAA preparation seems to help HCC patients undergoing radiotherapy by increasing the BCAA concentration.

Citations

Citations to this article as recorded by

Research advances in branched-chain amino acid metabolism in tumors
Zheng Li, Sainan Chen, Xuechao Wu, Fei Liu, Jing Zhu, Jiayi Chen, Xiaojie Lu, Rui Chi
Molecular and Cellular Biochemistry.2025; 480(5): 2707. CrossRef
Unveiling the Maze: Branched-Chain Amino Acids Fueling the Dynamics of Cancer Metabolism and Progression
Kai Xu, Pratham Shah, Dhruvi Makhanasa, Md. Wasim Khan
Cancers.2025; 17(11): 1751. CrossRef
Branched-Chain Amino Acids in Liver Diseases: Complexity and Controversy
Yaqi Zhang, Luqi Zhan, Lingjian Zhang, Qingmiao Shi, Lanjuan Li
Nutrients.2024; 16(12): 1875. CrossRef
Systematic review with meta‐analysis: Branched‐chain amino acid supplementation in liver disease
Anne M. van Dijk, Alexandra S. Bruins Slot, Piero Portincasa, Sebastiaan N. Siegerink, Najiba Chargi, Carina J. R. Verstraete, Joep de Bruijne, Frank P. Vleggaar, Karel J. van Erpecum
European Journal of Clinical Investigation.2023;[Epub] CrossRef
The Role of Branched-Chain Amino Acid Supplementation in Combination with Locoregional Treatments for Hepatocellular Carcinoma: Systematic Review and Meta-Analysis
Georgios A. Sideris, Savvas Tsaramanidis, Aikaterini T. Vyllioti, Njogu Njuguna
Cancers.2023; 15(3): 926. CrossRef
Plasma metabolomic signatures from patients following high-dose total body irradiation
Xiedong Hong, Lang Tian, Qiong Wu, Liming Gu, Wenli Wang, Hanxu Wu, Mingxiao Zhao, Xiaojin Wu, Chang Wang
Molecular Omics.2023; 19(6): 492. CrossRef
Use of Branched-Chain Amino Acids as a Potential Treatment for Improving Nutrition-Related Outcomes in Advanced Chronic Liver Disease
Santo Colosimo, Simona Bertoli, Francesca Saffioti
Nutrients.2023; 15(19): 4190. CrossRef
Efficacy of branched chain amino acids supplementation in liver cirrhosis: A systematic review and meta-analysis
Georgios Konstantis, Chryssa Pourzitaki, Michail Chourdakis, Elisavet Kitsikidou, Georgios Germanidis
Clinical Nutrition.2022; 41(6): 1171. CrossRef
Serum Amino Acid Profiles Predict the Development of Hepatocellular Carcinoma in Patients with Chronic HBV Infection
Tao Wu, Xiaojiao Zheng, Ming Yang, Aihua Zhao, Hongjiao Xiang, Tianlu Chen, Wei Jia, Guang Ji
ACS Omega.2022; 7(18): 15795. CrossRef
Diet high in branched-chain amino acid promotes PDAC development by USP1-mediated BCAT2 stabilization
Jin-Tao Li, Kai-Yue Li, Ying Su, Yuan Shen, Ming-Zhu Lei, Fan Zhang, Miao Yin, Zheng-Jun Chen, Wen-Yu Wen, Wei-Guo Hu, Dan Su, Jia Qu, Qun-Ying Lei
National Science Review.2022;[Epub] CrossRef
Diet and liver cancer risk: a narrative review of epidemiological evidence
Wan-Shui Yang, Xu-Fen Zeng, Zhi-Ning Liu, Qi-Hong Zhao, Yu-Ting Tan, Jing Gao, Hong-Lan Li, Yong-Bing Xiang
British Journal of Nutrition.2020; 124(3): 330. CrossRef
Multifaceted role of branched-chain amino acid metabolism in cancer
Hui Peng, Yingfei Wang, Weibo Luo
Oncogene.2020; 39(44): 6747. CrossRef
Effects of branched‐chain amino acids on postoperative tumor recurrence in patients undergoing curative resection for hepatocellular carcinoma: A randomized clinical trial
Hiroyuki Hachiya, Taku Aoki, Yukihiro Iso, Takayuki Shimizu, Kazuma Tago, Kyung Hwa Park, Yuhki Sakuraoka, Takayuki Shiraki, Shozo Mori, Keiichi Kubota
Journal of Hepato-Biliary-Pancreatic Sciences.2020; 27(11): 819. CrossRef
GATA-type transcription factors play a vital role in radiation sensitivity of Cryptococcus neoformans by regulating the gene expression of specific amino acid permeases
Wanchang Cui, XiangHong Li, Lisa Hull, Mang Xiao
Scientific Reports.2019;[Epub] CrossRef
Skeletal Muscle Depletion Predicts the Prognosis of Patients With Hepatocellular Carcinoma Treated With Radiotherapy
Joongyo Lee, Yeona Cho, Sangjoon Park, Jun Won Kim, Ik Jae Lee
Frontiers in Oncology.2019;[Epub] CrossRef
Effects of branched chain amino acid supplementation on patient care outcomes in adults and children with liver cirrhosis: A systematic review
P.H. Ooi, S.M. Gilmour, J. Yap, D.R. Mager
Clinical Nutrition ESPEN.2018; 28: 41. CrossRef
Manejo dietético y suplementación con aminoácidos de cadena ramificada en cirrosis hepática
A. Ruiz-Margáin, O. Méndez-Guerrero, B.M. Román-Calleja, S. González-Rodríguez, G. Fernández-del-Rivero, P.A. Rodríguez-Córdova, A. Torre, R.U. Macías-Rodríguez
Revista de Gastroenterología de México.2018; 83(4): 424. CrossRef
Dietary management and supplementation with branched-chain amino acids in cirrhosis of the liver
A. Ruiz-Margáin, O. Méndez-Guerrero, B.M. Román-Calleja, S. González-Rodríguez, G. Fernández-del-Rivero, P.A. Rodríguez-Córdova, A. Torre, R.U. Macías-Rodríguez
Revista de Gastroenterología de México (English Edition).2018; 83(4): 424. CrossRef
Effects of branched-chain amino acid supplementation after radiofrequency ablation for hepatocellular carcinoma: A randomized trial
Shunsuke Nojiri, Kei Fujiwara, Noboru Shinkai, Etsuko Iio, Takashi Joh
Nutrition.2017; 33: 20. CrossRef
Chronic Intake of Japanese Sake Mediates Radiation-Induced Metabolic Alterations in Mouse Liver
Tetsuo Nakajima, Guillaume Vares, Bing Wang, Mitsuru Nenoi, Albert J. Fornace
PLOS ONE.2016; 11(1): e0146730. CrossRef
Effects of Oral Branched‐Chain Amino Acids on Hepatic Encephalopathy and Outcome in Patients With Liver Cirrhosis
Takumi Kawaguchi, Eitaro Taniguchi, Michio Sata
Nutrition in Clinical Practice.2013; 28(5): 580. CrossRef

11,920 View
126 Download
21 Crossref

Intrapleural Chemotherapy with Cisplatin and Cytarabine in the Management of Malignant Pleural Effusion: Kee Won Kim, Suk Young Park, Myung Sook Kim, Seok Chan Kim, Eun Hee Lee, So Young Shin, Jong Ho Lee, Jong Bum Kweon, Kuhn Park; Cancer Res Treat. 2004;36(1):68-71. Published online February 29, 2004; DOI: https://doi.org/10.4143/crt.2004.36.1.68

Abstract PDF PubReader ePub

Purpose

The purpose of this study was to evaluate the efficacy of intrapleural chemotherapy (IPC) with cisplatin and cytarabine in the management of malignant pleural effusion (MPE) from non-small-cell lung cancer (NSCLC).

Materials and Methods

A prospective analysis was carried out on 40 patients with pathologically proven MPE from NSCLC who had received IPC. A single dose of cisplatin 100 mg/m² plus cytarabine 1200 mg/m² in 250 ml normal saline was instilled into the pleural space via a chest tube and drained 4 hours later. Patients were evaluated for toxicities and responses at 1, 2, & 3 weeks and then at monthly intervals if possible. Systemic chemotherapy was administered, if the patient agreed to receive it, after achieving complete control (CC) of MPE.

Results

The median duration of chest tube insertion for drainage was 7 (3~32) days. Among the assessable 37 patients, CC and partial control (PC) were 32 (86.5%) and 4 (10.8%) patients, respectively (overall response rate 97.3%). The median duration of response was 12 months (2~23) and there were only two relapses of IPC after achieving CC. Among the 35 patients who were assessable until they died, 28 patients (80.0%) maintained CC until the last follow-up. There was only one toxic death and the toxicities of IPC, versus the results obtained, were deemed acceptable.

Conclusion

The procedures were tolerable to the patients and chemotherapy-induced complications were at an acceptable level. The outcome of this trial indicates that IPC has a superior and long lasting treatment response in the management of patients with MPE from NSCLC.

Citations

Citations to this article as recorded by

Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion
Zihui Li, Jie Deng, Fei Yan, Li Liu, Yanling Ma, Jianhai Sun
Scientific Reports.2023;[Epub] CrossRef
Survival Benefits for Pulmonary Adenocarcinoma With Malignant Pleural Effusion After Thoracoscopic Surgical Treatment: A Real-World Study
Xin Li, Mingbiao Li, Jinshuang Lv, Jinghao Liu, Ming Dong, Chunqiu Xia, Honglin Zhao, Song Xu, Sen Wei, Zuoqing Song, Gang Chen, Hongyu Liu, Jun Chen
Frontiers in Oncology.2022;[Epub] CrossRef
Modified indwelling pleural catheter versus silver nitrate pleurodesis for the management of malignant pleural effusion
Mohammed F. Abdelghany, Khaled Essmat, Atef Farouk El-Karn, Sahar Farghly Youssif
The Egyptian Journal of Chest Diseases and Tuberculosis.2022; 71(2): 248. CrossRef
Chinese herbal injections versus intrapleural cisplatin for lung cancer patients with malignant pleural effusion: A Bayesian network meta-analysis of randomized controlled trials
Yi-Fang Xu, Yun-Ru Chen, Fan-Long Bu, Yu-Bei Huang, Yu-Xin Sun, Cheng-Yin Li, Jodi Sellick, Jian-Ping Liu, Dan-Mei Qin, Zhao-Lan Liu
Frontiers in Oncology.2022;[Epub] CrossRef
Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy, Chigozirim N. Ekeke, Kira L. Russell, Samuel C. Butler, Yue Wang, James D. Luketich, Adam C. Soloff, Rajeev Dhupar, Michael T. Lotze
OncoImmunology.2019; 8(4): e1554969. CrossRef
Efficacy and safety of intrapleural cisplatin versus silver nitrate in treatment of malignant pleural effusion
Mohammad K. El Badrawy, Raed El-Metwally Ali, Asem A. Hewidy, Mohamed A. El-Layeh, Fatma M. F. Akl, Abdelhadi Shebl
Egyptian Journal of Bronchology.2018; 12(1): 98. CrossRef
Biodegradable drug-eluting pellets provide steady and sustainable cisplatin release in the intrapleural cavity: In vivo and in vitro studies
Yin-Kai Chao, Yu-Wen Wen, Kuo-Sheng Liu, Yi-Chuan Wang, Chih-Wei Wang, Shih-Jung Liu
International Journal of Pharmaceutics.2015; 484(1-2): 38. CrossRef

9,271 View
58 Download
7 Crossref

First
Prev
Page of 1
Next
Last

Search